A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2019
Price : $35 *
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Amgen
- 17 Sep 2019 According to an Amgen media release, data showing the two-year results will be presented as a late-breaking abstract in an oral presentation at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, Sept. 27-Oct. 1, 2019.
- 04 Jun 2019 Interim results assessing one-year recurrence-free survival (RFS), presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 21 Jun 2018 Planned primary completion date changed from 20 Apr 2019 to 30 Apr 2019.